DC
LYEL icon

Decheng Capital’s Lyell Immunopharma LYEL Stock Holding History

Decheng Capital’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.72M Hold
692,050
– – 1.33% 9
2026
Q1 		$13.9M Hold
692,050
– – 2.1% 6
2025
Q4 		$21.3M Buy
692,050
+96,584
+16% +$2.16M 2.87% 5
2025
Q3 		$9.67M Hold
595,466
– – 1.69% 8
2025
Q2 		$5.26M Sell
595,466
-1
-0% -$9 1.33% 12
2025
Q1 		$6.41M Hold
595,467
– – 1.8% 11
2024
Q4 		$7.62M Buy
+595,467
New +$11.8M 1.63% 13

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Decheng Capital's LYEL Position: Q2 2026 in Review

Decheng Capital held its Lyell Immunopharma (LYEL) position steady in Q2 2026 at 692,050 shares worth $9.72M. The position accounts for 1.33% of the portfolio, ranked #9.

Decheng Capital first reported a position in LYEL in Q4 2024 and has held it in 7 quarters since. The position peaked at $21.3M in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Decheng Capital held 692,050 shares of Lyell Immunopharma worth $9.72M as of Q2 2026.
  • Decheng Capital left its Lyell Immunopharma share count unchanged in Q2 2026.
  • Lyell Immunopharma made up 1.33% of Decheng Capital's portfolio in Q2 2026, its #9 holding.
  • Decheng Capital first reported a position in Lyell Immunopharma in Q4 2024 and has held it in 7 quarters since.
  • Decheng Capital's Lyell Immunopharma position peaked at $21.3M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.